Adt ( ($ADT) ) has provided an update. On October 24, 2025, ADT Inc.’s subsidiaries entered into an amendment to their existing credit agreement, ...

Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer reduced the risk of developing metastases and castration-resistant disease, ...

Pulse Biosciences (Nasdaq:PLSE) today announced the enrollment of the first patient in its NANOCLAMP AF study for treating ...

ARPIs used in combination with ADT in prostate cancer significantly increased the risk for cardiovascular events.

A new study shows that the use of a simple maternity innovation that measures the mother's blood pressure and pulse can be ...

With a minimalist design, premium finish options, and flexible placement, the Bluesound PULSE FLEX seamlessly blends into ...

HAYWARD, Calif., October 10, 2025--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ ...

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery ...

COPENHAGEN - Pulse Biosciences, Inc. (NASDAQ:PLSE), a medical device company with a market capitalization of $1.3 billion and trading near its 52-week high of $25, announced positive initial results ...